Heart attack

Carvedilol-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Carvedilol (Brand name: Coreg), a non-selective beta blocker used to treat congestive heart failure, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, , 9/April/2019, 11.17 pm
Carvedilol-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Carvedilol (Brand name: Coreg), a non-selective beta blocker used to treat congestive heart failure, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, , 9/April/2019, 11.17 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April…

read more

Mechanistic insights into why consumption of high fact diet is bad for your heart: High fat diet promotes DNA damage responses, decreases telomerase expression, accelerates telomere shortening, and decreases cardiomyocyte survival after myocardial infarction, via downregulation of PNUTS, 8/April/2019, 11.38 pm
Mechanistic insights into why consumption of high fact diet is bad for your heart: High fat diet promotes DNA damage responses, decreases telomerase expression, accelerates telomere shortening, and decreases cardiomyocyte survival after myocardial infarction, via downregulation of PNUTS, 8/April/2019, 11.38 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac aging and function.” This study was published, in the 7 March  2013 issue of the journal Nature,  by Prof Dimmler, Boon, and…

read more

Intracardiac injection of Erythropoietin/Hematopoietin attenuates pathogenesis-associated with Myocardial infarction: Erythropoietin/Hematopoietin decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target gene, 31/March/2019, 9.29 am
Intracardiac injection of Erythropoietin/Hematopoietin attenuates pathogenesis-associated with Myocardial infarction: Erythropoietin/Hematopoietin decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target gene, 31/March/2019, 9.29 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston,…

read more

Intracardiac/epicardial injection of Cyclic Helix-B peptide (CHBP) protects against and promotes functional recovery after Myocardial Infarction:  CHBP, derived from erythropoietin/hematopoietin, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 31/March/2019, 9.02 am
Intracardiac/epicardial injection of Cyclic Helix-B peptide (CHBP) protects against and promotes functional recovery after Myocardial Infarction:  CHBP, derived from erythropoietin/hematopoietin, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 31/March/2019, 9.02 am 960 720 Dr Boomi's Genom-2-Discovery Center

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of the journal Nature,  by Prof Dimmler,…

read more

Intracardiac injection of Erythropoietin/Hematopoietin promotes heart regeneration and repair: Intracardiac injection of Erythropoietin/Hematopoietin decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 30/March/2019, 12.20 am
Intracardiac injection of Erythropoietin/Hematopoietin promotes heart regeneration and repair: Intracardiac injection of Erythropoietin/Hematopoietin decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 30/March/2019, 12.20 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and…

read more

Intracardiac/Epicardial injection of Erythropoietin/Hematopoietin  may attenuate pathogenesis-associated with Myocardial infarction: Erythropoietin/Hematopoietin decreases GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, and promotes heart healing via up regulation of its target gene, 30/March/2019, 12.04 am
Intracardiac/Epicardial injection of Erythropoietin/Hematopoietin  may attenuate pathogenesis-associated with Myocardial infarction: Erythropoietin/Hematopoietin decreases GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, and promotes heart healing via up regulation of its target gene, 30/March/2019, 12.04 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; and Center for Systems Biology, Massachusetts General Hospital…

read more
Start Typing